Skip to main content
. 2020 Aug 18;16(1):21–28. doi: 10.1016/j.jds.2020.07.013

Figure 4.

Fig. 4

Immunohistochemical staining of SPRY1 protein in human oral potentially malignant disorders (OPMDs) with and without malignant transformation (MT). Representative stronger immunohistochemical staining of SPRY1 protein in a human OPMD with MT (A, ×100) and weaker staining of SPRY1 protein in a human OPMD without MT (B, ×100).